Analysis of m6A methylation patterns and tumor microenvironment in endometrial cancer
Analysis of m6A methylation patterns and tumor microenvironment in endometrial cancer
复制标题
子宫内膜癌m6A甲基化模式及肿瘤微环境分析
DOI：
10.1016/j.gene.2022.147052
复制
发表时间：
2022-11-25
期刊：
影响因子：
3.5
通讯作者：
Zhang, Yongli
中科院分区：
文献类型：
--
作者：
Chen, Junfeng;Luo, Xiaomei;Zhang, Yongli
背景：N6-甲基腺苷(M6A)修饰是真核基因中最常见的表观遗传修饰。近年来，大量研究表明，肿瘤微环境(TME)对肿瘤的生长和发展起着至关重要的作用。然而，关于子宫内膜癌中m6A甲基化与TME相互作用的研究很少。方法：根据21个子宫内膜癌患者和无肿瘤个体的21个m6A调节因子，构建了三种不同的m6A基因修饰模式。我们研究了m6A修饰模式与TME相关特征之间的关系。筛选差异表达基因，并建立M6A评分来评估UCEC患者的预后和免疫治疗效果。结果：我们发现了三种不同的M6A修饰模式。TME的浸润性特征与具有三种不同免疫表型的肿瘤高度一致。此外，我们的分析表明，M6A评分在预测临床结果方面是有用的。M6A评分低的患者预后更好，免疫治疗反应更强，肿瘤突变负担更高。结论：本研究探讨了M6A修饰和TME对肿瘤患者预后的影响，为寻找改善患者预后的免疫治疗策略提供参考。
Background: The N6-methyladenosine (m6A) modification is the most common epigenetic modification in eukaryotic mRNA. In recent years, lots of studies have shown that the tumor microenvironment (TME) plays a critical role in tumor growth and development. However, there are few studies on the interaction between m6A methylation and the TME in uterine corpus endometrial carcinoma (UCEC).Methods: Three distinct m6A modification patterns were based on 21 m6A regulators of UCEC patients and tumor -free individuals. We investigated the relationship between m6A modification patterns and associated features of the TME. Differentially expressed genes were selected and the m6A score was established to evaluate the prognosis and immunotherapeutic efficacy of UCEC patients.Results: We identified three different m6A modification patterns. The TME infiltrating characteristics were highly consistent with tumors with three distinct immune phenotypes. Besides, our analysis showed that the m6A score was shown to be useful in predicting clinical outcomes. Patients with the low m6A score seemed to have a better prognosis, a stronger immunotherapeutic response, and a higher tumor mutation burden.Conclusion: Our study explored the influence of m6A modification and TME on the prognosis of cancer patients, which will contribute to the discovery of immunotherapy strategies to improve their prognosis.